EA201790515A1 - Противовирусные соединения - Google Patents

Противовирусные соединения

Info

Publication number
EA201790515A1
EA201790515A1 EA201790515A EA201790515A EA201790515A1 EA 201790515 A1 EA201790515 A1 EA 201790515A1 EA 201790515 A EA201790515 A EA 201790515A EA 201790515 A EA201790515 A EA 201790515A EA 201790515 A1 EA201790515 A1 EA 201790515A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
virus compounds
virus
methods
administration
Prior art date
Application number
EA201790515A
Other languages
English (en)
Other versions
EA037281B1 (ru
Inventor
Хунянь Го
Дэррил Като
Торстен А. Киршберг
Хунтао Лю
Джон О. Линк
Майкл Л. Митчелл
Джей П. Перриш
Нил Сквайерс
Цзяньюй Сунь
Джеймс Тейлор
Элизабет М. Бейкон
Эда Каналес
Чон Ю. Ким
Эзоп Чо
Джероми Дж. Коттелл
Манодж С. Десай
Рэндалл Л. Хэлкомб
Эван С. Криговский
Скотт И. Лазервит
Ци Лю
Ричард Макман
Хьюн-Цзюн Пюнь
Джозеф Х. Сожье
Джеймс Д. Тренкл
Уинстон С. Це
Рэндалл В. Вивиан
Скотт Д. Шрёдер
Уильям Дж. Уоткинс
Ляньхун Сюй
Чжэн-Юй Ян
Терри Келлар
Сяонин Шэн
Майкл О'Нил Ханрахан Кларк
Чиэнь-хун Чоу
Майкл Грауп
Хаолунь Цзинь
Райан Макфадден
Майкл Р. Миш
Самуэль Е. Метобо
Бартон В. Филлипс
Чандрасекар Венкатарамани
Original Assignee
Джилид Фармассет Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42645241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790515(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Фармассет Ллс filed Critical Джилид Фармассет Ллс
Publication of EA201790515A1 publication Critical patent/EA201790515A1/ru
Publication of EA037281B1 publication Critical patent/EA037281B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

Настоящее изобретение относится к противовирусным соединениям, композициям, включающим такие соединения, и способам лечения, которые включают введение таких соединений, а также к способам и промежуточным соединениям, пригодным для получения таких соединений.
EA201790515A 2009-05-13 2010-05-12 Способы получения противовирусного соединения EA037281B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17797209P 2009-05-13 2009-05-13
US22474509P 2009-07-10 2009-07-10
US23876009P 2009-09-01 2009-09-01

Publications (2)

Publication Number Publication Date
EA201790515A1 true EA201790515A1 (ru) 2018-10-31
EA037281B1 EA037281B1 (ru) 2021-03-04

Family

ID=42645241

Family Applications (5)

Application Number Title Priority Date Filing Date
EA201490854A EA026536B1 (ru) 2009-05-13 2010-05-12 Противовирусные соединения
EA201790515A EA037281B1 (ru) 2009-05-13 2010-05-12 Способы получения противовирусного соединения
EA201490853A EA201490853A1 (ru) 2009-05-13 2010-05-12 Противовирусные соединения
EA201190259A EA021974B1 (ru) 2009-05-13 2010-05-12 Противовирусное соединение
EA201590073A EA027493B1 (ru) 2009-05-13 2010-05-12 Промежуточные соединения для получения противовирусного соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201490854A EA026536B1 (ru) 2009-05-13 2010-05-12 Противовирусные соединения

Family Applications After (3)

Application Number Title Priority Date Filing Date
EA201490853A EA201490853A1 (ru) 2009-05-13 2010-05-12 Противовирусные соединения
EA201190259A EA021974B1 (ru) 2009-05-13 2010-05-12 Противовирусное соединение
EA201590073A EA027493B1 (ru) 2009-05-13 2010-05-12 Промежуточные соединения для получения противовирусного соединения

Country Status (40)

Country Link
US (8) US8088368B2 (ru)
EP (6) EP3002281B1 (ru)
JP (7) JP5582662B2 (ru)
KR (8) KR101727876B1 (ru)
CN (8) CN102596936B (ru)
AP (2) AP2016008993A0 (ru)
AR (1) AR076765A1 (ru)
AU (1) AU2010249043B2 (ru)
BR (3) BR122014012810B1 (ru)
CA (2) CA2761258C (ru)
CL (1) CL2011002825A1 (ru)
CO (1) CO6470842A2 (ru)
CY (4) CY1116942T1 (ru)
DK (3) DK3002281T3 (ru)
EA (5) EA026536B1 (ru)
EC (1) ECSP11011517A (ru)
ES (4) ES2548156T3 (ru)
FR (1) FR16C0005I2 (ru)
HK (4) HK1207638A1 (ru)
HR (3) HRP20151000T8 (ru)
HU (4) HUE036906T2 (ru)
IL (5) IL216254A (ru)
LT (3) LT3002281T (ru)
ME (3) ME02321B (ru)
MX (6) MX2011012058A (ru)
NL (1) NL300796I2 (ru)
NO (3) NO3002281T3 (ru)
NZ (3) NZ706236A (ru)
PE (2) PE20120509A1 (ru)
PL (4) PL3309157T3 (ru)
PT (4) PT2873665T (ru)
RS (3) RS54386B8 (ru)
SG (2) SG176015A1 (ru)
SI (4) SI3002281T1 (ru)
SM (2) SMT201500284B (ru)
TW (7) TW201503888A (ru)
UA (1) UA121454C2 (ru)
UY (1) UY32629A (ru)
WO (1) WO2010132601A1 (ru)
ZA (1) ZA201108436B (ru)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
NZ582692A (en) * 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2010065674A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8865756B2 (en) * 2008-12-03 2014-10-21 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8637561B2 (en) * 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
BRPI1016172A2 (pt) * 2009-04-24 2016-04-19 Tibotec Pharm Ltd éteres diarílicos
WO2010132538A1 (en) * 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
RS54386B8 (sr) * 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010138791A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
CA2762885A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
SI2628481T1 (sl) * 2009-06-11 2016-08-31 Abb Vie Bahamas Limited Trisubstituirani heterocikli kot inhibitorji replikacije HCV virusa hepatitisa C
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8609648B2 (en) * 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011015657A1 (en) * 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
AU2010280712B2 (en) * 2009-08-07 2015-10-22 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives as hepatitis C virus inhibitors
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (ru) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензимидазолимидазольные производные
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AU2010325980B2 (en) * 2009-12-04 2016-04-07 National Health Research Institutes Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104341401B (zh) * 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
MX2012006877A (es) * 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
MX2012007420A (es) * 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2787309A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2013518062A (ja) * 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A4 (en) * 2010-03-04 2014-05-14 Enanta Pharm Inc PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
MX2012010918A (es) * 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
EP2550268A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
EP2575475A4 (en) * 2010-05-28 2013-11-27 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
AR081848A1 (es) * 2010-06-09 2012-10-24 Presidio Pharmaceuticals Inc Inhibidores de la proteina ns5a del vhc
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) * 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012020036A1 (en) * 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012027712A2 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
NZ726475A (en) * 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
RU2452735C1 (ru) * 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20150232455A1 (en) * 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
US20140364616A1 (en) * 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
US20140343286A1 (en) * 2010-12-15 2014-11-20 Allan C. Krueger Anti-viral compounds
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012188400A (ja) * 2011-03-11 2012-10-04 Tosoh Corp ジチエノベンゾジチオフェンの製造方法
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
US20120252721A1 (en) * 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709455A4 (en) 2011-05-18 2014-11-05 Enanta Pharm Inc PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
EA201791776A1 (ru) 2011-05-27 2018-04-30 Ачиллион Фармасьютикалз, Инк. Замещенные циклофаны для использования при лечении инфекции вгс
WO2013007106A1 (zh) 2011-07-09 2013-01-17 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的螺环化合物
WO2013021344A1 (en) 2011-08-08 2013-02-14 Lupin Limited Imidazole derivatives as antiviral agents
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
KR20140065427A (ko) * 2011-08-24 2014-05-29 글락소스미스클라인 엘엘씨 Ｃ형 간염에 대한 조합 치료
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
SG11201400664WA (en) * 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012013117U1 (de) * 2011-10-21 2015-01-16 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
DE112012003510T5 (de) * 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
RU2625787C2 (ru) 2011-11-03 2017-07-19 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент { 2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил} амина
CN103328480B (zh) 2011-11-16 2016-05-25 吉利德法莫赛特有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
CN104203940B (zh) 2011-12-28 2017-01-18 爱尔兰詹森科学公司 作为hcv抑制剂的杂双环衍生物
MX2014008008A (es) * 2011-12-29 2014-08-21 Abbvie Inc Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
IN2014MN01547A (ru) * 2012-02-10 2015-05-08 Lupin Ltd
AU2013221571A1 (en) * 2012-02-14 2014-08-28 University Of Georgia Research Foundation, Inc. Spiro [2.4] heptanes for treatment of Flaviviridae infections
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
ES2624846T3 (es) 2012-04-25 2017-07-17 Theravance Biopharma R&D Ip, Llc Compuestos de piperazina-piperidina como inhibidores del virus de la hepatitis C
EP2850072B1 (en) 2012-04-25 2016-08-31 Theravance Biopharma R&D IP, LLC Hepatitis c virus inhibitors
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) * 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
TWI610916B (zh) * 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) * 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
WO2014082379A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
WO2014082381A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2014082380A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN103880823B (zh) * 2012-12-21 2017-12-05 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
RU2507201C1 (ru) * 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2518369C1 (ru) * 2013-02-07 2014-06-10 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201439060A (zh) * 2013-02-27 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20140357595A1 (en) * 2013-06-04 2014-12-04 Gilead Pharmasset Llc Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
US9334291B2 (en) * 2013-06-06 2016-05-10 AB Pharma Ltd. Antiviral compounds highly effective as HCV-NS5A inhibitor
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CN104610272B (zh) * 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015096674A1 (zh) * 2013-12-23 2015-07-02 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
CN105873922B (zh) * 2013-12-31 2018-08-14 南京圣和药业股份有限公司 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015110048A1 (en) * 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
CN104860931A (zh) 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CN104140417B (zh) * 2014-06-11 2016-04-06 苏州景泓生物技术有限公司 合成gs5885用的中间体的先期化合物的合成方法
CN105524049B (zh) * 2014-09-28 2018-11-06 正大天晴药业集团股份有限公司 氘代的丙型肝炎病毒ns5a蛋白抑制剂
CN104513147B (zh) * 2014-11-20 2016-05-11 上海众强药业有限公司 芴乙酮衍生物的制备方法
TWI675029B (zh) * 2014-12-16 2019-10-21 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的橋環化合物及其製備方法
WO2016103232A1 (en) * 2014-12-24 2016-06-30 Granules India Limited An improved process for the preparation of hcv inhibitor
CN104530016A (zh) * 2014-12-25 2015-04-22 上海泓博智源医药技术有限公司 一种雷迪帕韦的制备方法及其中间体
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
AU2016217952A1 (en) 2015-02-13 2017-09-28 Sandoz Ag Pharmaceutical compositions comprising Ledipasvir and Sofosbuvir
CN105985355B (zh) * 2015-03-01 2020-05-05 南京圣和药业股份有限公司 稠合三环类肝炎病毒抑制剂及其应用
ES2656225T3 (es) 2015-03-04 2018-02-26 Gilead Sciences, Inc. Receptor de tipo toll que modula compuestos de 4,6-diamino-pirido[3,2-d]pirimidina
WO2016145269A1 (en) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104829599B (zh) * 2015-03-17 2017-06-09 上海众强药业有限公司 雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN105017228A (zh) * 2015-07-03 2015-11-04 上海众强药业有限公司 一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法
CN111004167B (zh) 2015-07-24 2024-03-22 新联基因公司 1-甲基-d-色氨酸的盐和前药
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR101919194B1 (ko) * 2015-09-15 2018-11-15 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
WO2017072596A1 (en) 2015-10-26 2017-05-04 Optimus Drugs (P) Ltd An improved process for the preparation of ledipasvir
WO2017072714A1 (en) 2015-10-30 2017-05-04 Lupin Limited Stable ledipasvir premix and process of preparation thereof
CN108349945B (zh) * 2015-11-06 2021-10-29 江苏豪森药业集团有限公司 Hcv抑制剂、其制备方法与应用
CN106117187B (zh) * 2016-01-12 2019-01-01 深圳市塔吉瑞生物医药有限公司 一种丙型肝炎病毒抑制剂、药物组合物及其应用
EP3411369A1 (en) * 2016-02-01 2018-12-12 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
WO2017145028A1 (en) * 2016-02-26 2017-08-31 Glenmark Pharmaceuticals Limited Process for preparation of ledipasvir
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017195147A1 (en) * 2016-05-12 2017-11-16 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
KR102202984B1 (ko) 2016-05-27 2021-01-13 길리애드 사이언시즈, 인코포레이티드 Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN107663196A (zh) * 2016-07-27 2018-02-06 广东东阳光药业有限公司 制备化合物的方法
WO2018035410A1 (en) * 2016-08-19 2018-02-22 Temple University-Of The Commonwealth System Of Higher Education Compositions and methods of treatment using expanded-size dna analogs
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
CN106632275B (zh) * 2016-12-20 2018-03-06 上海同昌生物医药科技有限公司 一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
US10392370B2 (en) 2017-03-13 2019-08-27 Optimus Drugs Pvt Ltd Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
JP2020519647A (ja) 2017-05-12 2020-07-02 マヴァロン・セラピューティクス・リミテッド グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換複素環式化合物
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
IL300572A (en) 2018-02-13 2023-04-01 Gilead Sciences Inc PD–1/PD–L1 inhibitors
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2019222146A1 (en) * 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020219808A1 (en) * 2019-04-25 2020-10-29 Beta Pharma, Inc. Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4079748A1 (en) 2021-04-23 2022-10-26 Insusense ApS Modulators of sortilin activity
EP4089102A1 (en) 2021-05-14 2022-11-16 Insusense ApS Modulators of sortilin activity
WO2022246072A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
WO2023043816A1 (en) * 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023154528A1 (en) * 2022-02-11 2023-08-17 Wave Life Sciences Ltd. Stereoselective technologies for chiral compounds

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JPWO2008156094A1 (ja) 2007-06-19 2010-08-26 杏林製薬株式会社 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
MX2010008650A (es) 2008-02-12 2010-08-30 Bristol Myers Squibb Co Inhibidores de virus de la hepatitis c.
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0822323A2 (pt) 2008-02-13 2015-06-16 Bristol Myers Squibb Co Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2457659A (en) 2008-02-19 2009-08-26 Malcolm Mulheron Foldable meal tray
WO2010004843A1 (ja) 2008-07-08 2010-01-14 Ntn株式会社 減速装置
MX2011000060A (es) 2008-07-10 2011-02-22 Prosidion Ltd Agonistas del receptor acoplado a la proteina g piperidinilo.
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065674A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8865756B2 (en) 2008-12-03 2014-10-21 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
NZ595280A (en) 2009-02-27 2013-11-29 Enanta Pharm Inc Hepatitis c virus inhibitors
EA201190178A1 (ru) 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
BRPI1013394B1 (pt) 2009-03-27 2022-04-19 Merck Sharp & Dohme Corp Composto inibidor da replicação do vírus da hepatite c, sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, usos do composto e do sal farmaceuticamente aceitável do mesmo
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
BRPI1016172A2 (pt) 2009-04-24 2016-04-19 Tibotec Pharm Ltd éteres diarílicos
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
RS54386B8 (sr) * 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2762885A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
SI2628481T1 (sl) 2009-06-11 2016-08-31 Abb Vie Bahamas Limited Trisubstituirani heterocikli kot inhibitorji replikacije HCV virusa hepatitisa C
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
AU2010280712B2 (en) 2009-08-07 2015-10-22 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives as hepatitis C virus inhibitors
FR2949465B1 (fr) 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
EP2473503B1 (en) 2009-09-03 2014-07-23 Janssen R&D Ireland Bis-benzimidazole derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (ru) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензимидазолимидазольные производные
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
CN104341401B (zh) 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MX2012007420A (es) 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
KR20130008040A (ko) 2010-03-09 2013-01-21 머크 샤프 앤드 돔 코포레이션 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
NZ603310A (en) * 2010-05-21 2015-01-30 Gilead Sciences Inc Heterocyclic flaviviridae virus inhibitors
AR084393A1 (es) * 2010-06-10 2013-05-15 Gilead Sciences Inc Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
WO2012027712A2 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012041014A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
NZ726475A (en) 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
TW201701876A (zh) * 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
SG11201400664WA (en) * 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
CN103328480B (zh) 2011-11-16 2016-05-25 吉利德法莫赛特有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound

Also Published As

Publication number Publication date
AU2010249043A1 (en) 2011-12-01
UA121454C2 (uk) 2020-06-10
AP2011005987A0 (en) 2011-12-31
NL300796I2 (ru) 2016-06-30
CN103977406B (zh) 2016-10-19
HUE025983T2 (en) 2016-05-30
BR122014012810A2 (pt) 2017-06-27
HRP20161242T8 (hr) 2021-05-14
IL233042A0 (en) 2014-07-31
EP3626716A1 (en) 2020-03-25
CN109020961A (zh) 2018-12-18
EA027493B1 (ru) 2017-07-31
US20130137877A1 (en) 2013-05-30
CY2016001I1 (el) 2018-01-10
KR20140122706A (ko) 2014-10-20
BR122014013631A2 (pt) 2017-06-27
NO3002281T3 (ru) 2018-02-10
PT2430014E (pt) 2015-10-20
EP2430014A1 (en) 2012-03-21
KR101727876B1 (ko) 2017-04-17
HUE036906T2 (hu) 2018-08-28
US20170029408A1 (en) 2017-02-02
HK1253517A1 (zh) 2019-06-21
TW201503888A (zh) 2015-02-01
MX2011012058A (es) 2012-04-02
SI3309157T1 (sl) 2020-02-28
IL233679B (en) 2019-05-30
TW201617073A (zh) 2016-05-16
TWI689305B (zh) 2020-04-01
PT3002281T (pt) 2017-11-14
ES2646131T3 (es) 2017-12-12
EP3002281A1 (en) 2016-04-06
HRP20171759T8 (hr) 2021-05-14
HK1207638A1 (zh) 2016-02-05
BRPI1010795B1 (pt) 2018-12-11
US20140051656A1 (en) 2014-02-20
ES2758726T3 (es) 2020-05-06
LTC2430014I2 (lt) 2021-02-25
KR20170041924A (ko) 2017-04-17
US8273341B2 (en) 2012-09-25
TWI547495B (zh) 2016-09-01
JP5582662B2 (ja) 2014-09-03
RS56654B8 (sr) 2021-06-30
US8822430B2 (en) 2014-09-02
US20100310512A1 (en) 2010-12-09
NO2020046I1 (no) 2020-12-18
TW201105656A (en) 2011-02-16
HUS1600001I1 (hu) 2016-02-29
ZA201108436B (en) 2013-01-30
EP3002281B1 (en) 2017-09-13
CN104016971A (zh) 2014-09-03
DK3002281T3 (en) 2017-12-18
RS55249B8 (sr) 2021-06-30
SI2430014T1 (sl) 2015-10-30
ME02536B (me) 2017-02-20
US20140039021A1 (en) 2014-02-06
CN106588890B (zh) 2020-11-27
JP2012526838A (ja) 2012-11-01
TW201504244A (zh) 2015-02-01
CA2761258A1 (en) 2010-11-18
TW202042807A (zh) 2020-12-01
HK1223365A1 (zh) 2017-07-28
AU2010249043B2 (en) 2014-10-09
IL216254A (en) 2016-08-31
JP2019104732A (ja) 2019-06-27
RS54386B1 (en) 2016-04-28
US9981955B2 (en) 2018-05-29
TW201632183A (zh) 2016-09-16
KR20180028070A (ko) 2018-03-15
UY32629A (es) 2010-12-31
CN104211689B (zh) 2017-01-18
CN104211713A (zh) 2014-12-17
JP2014148550A (ja) 2014-08-21
CN102596936B (zh) 2014-06-11
AP3622A (en) 2016-03-02
AR076765A1 (es) 2011-07-06
CL2011002825A1 (es) 2012-10-12
JP5744283B2 (ja) 2015-07-08
CY1118048T1 (el) 2018-03-07
US8575118B2 (en) 2013-11-05
CY2016001I2 (el) 2018-01-10
BR122014012810B1 (pt) 2020-04-14
BR122014013631B8 (pt) 2021-05-25
PE20120509A1 (es) 2012-05-09
NO2016004I2 (no) 2016-02-29
CN106588890A (zh) 2017-04-26
US9511056B2 (en) 2016-12-06
EP2430014B1 (en) 2015-08-19
ME02916B (me) 2018-10-20
SI2873665T1 (sl) 2017-02-28
KR20140122705A (ko) 2014-10-20
FR16C0005I2 (fr) 2016-09-30
CN103977406A (zh) 2014-08-13
SI3002281T1 (sl) 2017-11-30
NZ706236A (en) 2016-07-29
RS54386B8 (sr) 2021-06-30
DK2873665T3 (en) 2016-11-07
IL233044A0 (en) 2014-07-31
MX363732B (es) 2019-04-01
MX360803B (es) 2018-11-16
CA2886322A1 (en) 2010-11-18
PL3002281T3 (pl) 2018-02-28
JP2014169331A (ja) 2014-09-18
HK1253517B (zh) 2020-04-24
EA026536B1 (ru) 2017-04-28
PT3309157T (pt) 2019-12-02
JP5745727B2 (ja) 2015-07-08
EA201490853A1 (ru) 2014-09-30
CY1119684T1 (el) 2018-04-04
EA201590073A1 (ru) 2015-06-30
US20120264711A1 (en) 2012-10-18
MX2019003738A (es) 2019-07-01
BR122014013631B1 (pt) 2020-11-17
CN104230900A (zh) 2014-12-24
ES2596247T3 (es) 2017-01-05
EP3309157B1 (en) 2019-09-04
EA021974B1 (ru) 2015-10-30
IL233044A (en) 2015-07-30
RS56654B1 (sr) 2018-03-30
IL233678B (en) 2019-05-30
SG10201402280QA (en) 2014-08-28
NO2016004I1 (no) 2016-02-17
PL3309157T3 (pl) 2020-03-31
PL2873665T3 (pl) 2017-01-31
EP2873665B1 (en) 2016-07-06
US20140249074A1 (en) 2014-09-04
SG176015A1 (en) 2011-12-29
HRP20151000T8 (hr) 2021-05-14
HRP20161242T1 (hr) 2016-11-18
EP2873665A1 (en) 2015-05-20
PT2873665T (pt) 2016-10-13
CN104016971B (zh) 2016-05-25
EP3309157A1 (en) 2018-04-18
JP2021001214A (ja) 2021-01-07
FR16C0005I1 (ru) 2016-03-25
EA037281B1 (ru) 2021-03-04
HRP20171759T1 (hr) 2017-12-29
BRPI1010795A2 (pt) 2016-12-20
IL233679A0 (en) 2014-09-30
KR20140014393A (ko) 2014-02-06
KR20190029771A (ko) 2019-03-20
RS55249B1 (sr) 2017-02-28
LT3002281T (lt) 2017-12-11
IL216254A0 (en) 2012-01-31
EP2857394A1 (en) 2015-04-08
CN104230900B (zh) 2018-10-19
ECSP11011517A (es) 2012-01-31
ME02321B (me) 2016-06-20
TWI629981B (zh) 2018-07-21
TWI465444B (zh) 2014-12-21
WO2010132601A1 (en) 2010-11-18
LTPA2016002I1 (lt) 2021-01-11
US20120157404A1 (en) 2012-06-21
MX360800B (es) 2018-11-16
ES2548156T3 (es) 2015-10-14
CY1116942T1 (el) 2017-04-05
HUE030465T2 (hu) 2017-05-29
LT2873665T (lt) 2016-10-25
CN102596936A (zh) 2012-07-18
CA2761258C (en) 2015-08-04
SMT201500284B (it) 2016-01-08
US8841278B2 (en) 2014-09-23
KR20160084478A (ko) 2016-07-13
KR101546119B1 (ko) 2015-08-20
NZ619205A (en) 2015-04-24
IL233678A0 (en) 2014-09-30
JP2017145254A (ja) 2017-08-24
PE20150202A1 (es) 2015-02-13
HK1162518A1 (en) 2012-08-31
MX2020011251A (es) 2020-11-12
HRP20151000T1 (hr) 2015-11-20
KR20200011049A (ko) 2020-01-31
EA201490854A1 (ru) 2014-09-30
SMT201600351B (it) 2016-11-10
DK2430014T3 (en) 2015-11-30
KR101503752B1 (ko) 2015-03-18
EA201190259A1 (ru) 2013-01-30
PL2430014T3 (pl) 2016-02-29
CO6470842A2 (es) 2012-06-29
US8669234B2 (en) 2014-03-11
AP2016008993A0 (en) 2016-01-31
CN104211713B (zh) 2017-04-12
CN104211689A (zh) 2014-12-17
TW201902477A (zh) 2019-01-16
JP2015157842A (ja) 2015-09-03
US8088368B2 (en) 2012-01-03
NZ596444A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
EA201190259A1 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA200971074A1 (ru) Антивирусные соединения
EA201790781A2 (ru) Противовирусные соединения
EA200971078A1 (ru) Противовирусные соединения
EA201492002A1 (ru) Противовирусные соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
EA201070988A1 (ru) Противовирусные терапевтические средства
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201490588A1 (ru) Способы лечения вируса гепатита с
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201500530A1 (ru) 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена